Products
Lenograstim is commercially available as an injection/infusion preparation (Granocyte). It has been approved in many countries since 1993.
Structure and properties
Lenograstim is a protein of 174 amino acids produced by biotechnology. The sequence corresponds to human granulocyte colony-stimulating factor (G-CSF). Unlike filgrastim, lenograstim is identical to G-CSF and is glycosylated.
Effects
Lenograstim (ATC L03AA10) promotes the generation of neutrophil granulocytes and their release from the bone marrow. A significant increase in neutrophils can be detected in the blood after only 24 hours. It thus reduces the risk of infectious diseases and neutropenic fever.
Indications
Lenograstim is mainly used to treat neutropenia (decrease in neutrophil granulocytes in the blood), for example in connection with chemotherapy.
Dosage
According to the SmPC. The drug is administered as an infusion or subcutaneous injection.
Contraindications
- Hypersensitivity
- Chemotherapy
- Myelodysplasia
- Chronic myeloid leukemia
For complete precautions, see the drug label.
Interactions
Myelosuppressive cytotoxic chemotherapy should not be administered on the same day.
Adverse effects
The most common potential adverse effects include pain, injection site reactions, and fever.
